Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.

Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS.

Hematol Oncol. 2017 Jan 8. doi: 10.1002/hon.2380. [Epub ahead of print]

PMID:
28066928
2.

Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.

Cohen JB, Behera M, Thompson CA, Flowers CR.

Blood. 2016 Dec 12. pii: blood-2016-08-685073. [Epub ahead of print]

PMID:
27956385
3.

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.

Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M.

Am J Hematol. 2017 Feb;92(2):161-170. doi: 10.1002/ajh.24615.

4.

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A.

Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X.

PMID:
27451390
5.

Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.

Cohen JB, Han X, Jemal A, Ward EM, Flowers CR.

Cancer. 2016 Aug 1;122(15):2356-63. doi: 10.1002/cncr.30068.

PMID:
27153197
6.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1543-51. doi: 10.1016/j.bbmt.2016.04.019. Review.

7.

GIFT4 fusokine converts leukemic B cells into immune helper cells.

Deng J, Pennati A, Cohen JB, Wu Y, Ng S, Wu JH, Flowers CR, Galipeau J.

J Transl Med. 2016 Apr 27;14(1):106. doi: 10.1186/s12967-016-0865-1.

8.

A Clinician's Approach to Double-Hit Lymphoma: Identification, Evaluation, and Management.

Staton AD, Cohen JB.

J Oncol Pract. 2016 Mar;12(3):232-8. doi: 10.1200/JOP.2015.009647.

PMID:
26962166
9.

De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.

Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Iris Lim H, Martin P, Cohen JB, Evens A, Al-Mansour Z, Singavi A, Fenske TS, Blum KA.

Am J Hematol. 2016 Jun;91(4):395-9. doi: 10.1002/ajh.24299.

PMID:
26800311
10.

A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.

Flowers CR, Brown JR, Rosenthal H, Stock W, Katzen HI, Cohen JB, Sinha R, Lakhanpal S, Leis JF, Waller EK, Jaye DL.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):694-8. doi: 10.1016/j.clml.2015.07.640.

PMID:
26385641
11.

Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.

Cohen JB, Bucur S, Winton EF, Sinha R, Heffner LT, King N, Lonial S, Langston AA, Waller EK, Hutchison-Rzepka A, Colbert A, Lechowicz MJ, Flowers CR.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):514-8. doi: 10.1016/j.clml.2015.06.009.

PMID:
26297176
12.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2091-9. doi: 10.1016/j.bbmt.2015.07.028.

13.

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.

Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka A, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR.

Br J Haematol. 2015 Nov;171(4):539-46. doi: 10.1111/bjh.13637.

14.

A Plethora of Novel Therapies--Which One to Choose?

Cohen JB, Flowers CR.

Oncology (Williston Park). 2015 Jul;29(7):499-500. No abstract available.

15.

Next-generation surveillance strategies for patients with lymphoma.

Cohen JB, Kurtz DM, Staton AD, Flowers CR.

Future Oncol. 2015;11(13):1977-91. doi: 10.2217/fon.15.92. Review.

16.

Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.

Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M; Center for International Blood and Marrow Transplant Research Lymphoma Working Committee..

Biol Blood Marrow Transplant. 2015 Sep;21(9):1605-11. doi: 10.1016/j.bbmt.2015.05.007.

17.

Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma.

Davis CC, Cohen JB, Shah KS, Hutcherson DA, Surati MJ, Valla K, Panjic EH, Handler CE, Switchenko JM, Flowers CR.

Clin Lymphoma Myeloma Leuk. 2015 May;15(5):270-7. doi: 10.1016/j.clml.2014.12.011.

18.

Optimal disease surveillance strategies in non-Hodgkin lymphoma.

Cohen JB, Flowers CR.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):481-7. doi: 10.1182/asheducation-2014.1.481. Review.

PMID:
25696898
19.

Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.

Cohen JB, Ruppert AS, Heerema NA, Andritsos LA, Jones JA, Porcu P, Baiocchi R, Christian BA, Byrd JC, Flynn J, Penza S, Devine SM, Blum KA.

Clin Lymphoma Myeloma Leuk. 2015 May;15(5):278-285.e1. doi: 10.1016/j.clml.2014.12.012.

PMID:
25660723
20.

Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era.

Flowers CR, Cohen JB, Khan MK.

Leuk Lymphoma. 2015 Mar;56(3):557-8. doi: 10.3109/10428194.2014.970547. No abstract available.

PMID:
25315073
Items per page

Supplemental Content

Loading ...
Support Center